TAZVERIK Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Tazverik, and when can generic versions of Tazverik launch?
Tazverik is a drug marketed by Epizyme Inc and is included in one NDA. There are twenty-two patents protecting this drug.
This drug has three hundred and eighty-two patent family members in thirty-nine countries.
The generic ingredient in TAZVERIK is tazemetostat hydrobromide. One supplier is listed for this compound. Additional details are available on the tazemetostat hydrobromide profile page.
DrugPatentWatch® Generic Entry Outlook for Tazverik
Tazverik was eligible for patent challenges on January 23, 2024.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be December 19, 2035. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for TAZVERIK
International Patents: | 382 |
US Patents: | 22 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 90 |
Clinical Trials: | 13 |
Patent Applications: | 346 |
Drug Prices: | Drug price information for TAZVERIK |
What excipients (inactive ingredients) are in TAZVERIK? | TAZVERIK excipients list |
DailyMed Link: | TAZVERIK at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for TAZVERIK
Generic Entry Date for TAZVERIK*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for TAZVERIK
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Jacob Soumerai, MD | Phase 1/Phase 2 |
MEI Pharma, Inc. | Phase 1/Phase 2 |
Weill Medical College of Cornell University | Phase 1 |
Pharmacology for TAZVERIK
Anatomical Therapeutic Chemical (ATC) Classes for TAZVERIK
US Patents and Regulatory Information for TAZVERIK
TAZVERIK is protected by thirty-eight US patents and three FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of TAZVERIK is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting TAZVERIK
Aryl- or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA
Salt form of a human histone methyltransferase EZH2 inhibitor
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA BY INHIBITING ENHANCER OF ZESTE HOMOLOG 2 (EZH2)
Salt form of a human histone methyltransferase EZH2 inhibitor
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION BY INHIBITING EZH2
Salt form of a human histone methyltransferase EZH2 inhibitor
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA BY INHIBITING EZH2
Method for treating cancer
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA
Method for treating cancer
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Method for treating cancer
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Aryl-or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA
Aryl-or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Aryl-or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Method for treating cancer
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Salt form of a human histone methyltransferase EZH2 inhibitor
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Aryl-or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA
Aryl-or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Aryl-or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA
Aryl- or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Inhibitors of human EZH2 and methods of use thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Aryl- or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Aryl- or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Inhibitors of human EZH2 and methods of use thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Aryl- or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Inhibitors of human EZH2, and methods of use thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Inhibitors of human EZH2, and methods of use thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Inhibitors of human EZH2, and methods of use thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Salt form of a human histone methyltransferase EZH2 inhibitor
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Salt form of a human histone methyltransferase EZH2 inhibitor
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Aryl- or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA
Aryl- or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Aryl- or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Methods of treating cancer
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA
Aryl-or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA
Method for treating cancer
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA
Method for treating cancer
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Method for treating cancer
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Inhibitors of human EZH2, and methods of use thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION BY INHIBITING EZH2
FDA Regulatory Exclusivity protecting TAZVERIK
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up
INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA WHOSE TUMORS ARE POSITIVE FOR AN EZH2 MUTATION AS DETECTED BY AN FDA-APPROVED TEST AND WHO HAVE RECEIVED AT LEAST 2 PRIOR SYSTEMIC THERAPIES, AND FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS
Exclusivity Expiration: ⤷ Sign Up
INDICATED FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS AGED 16 YEARS AND OLDER WITH METASTATIC OR LOCALLY ADVANCED EPITHELIOID SARCOMA NOT ELIGIBLE FOR COMPLETE RESECTION
Exclusivity Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Epizyme Inc | TAZVERIK | tazemetostat hydrobromide | TABLET;ORAL | 211723-001 | Jan 23, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Epizyme Inc | TAZVERIK | tazemetostat hydrobromide | TABLET;ORAL | 211723-001 | Jan 23, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Epizyme Inc | TAZVERIK | tazemetostat hydrobromide | TABLET;ORAL | 211723-001 | Jan 23, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Epizyme Inc | TAZVERIK | tazemetostat hydrobromide | TABLET;ORAL | 211723-001 | Jan 23, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Epizyme Inc | TAZVERIK | tazemetostat hydrobromide | TABLET;ORAL | 211723-001 | Jan 23, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Epizyme Inc | TAZVERIK | tazemetostat hydrobromide | TABLET;ORAL | 211723-001 | Jan 23, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for TAZVERIK
When does loss-of-exclusivity occur for TAZVERIK?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 15350108
Estimated Expiration: ⤷ Sign Up
Patent: 21204706
Estimated Expiration: ⤷ Sign Up
Patent: 24201171
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 2017010166
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 67664
Estimated Expiration: ⤷ Sign Up
China
Patent: 7249591
Estimated Expiration: ⤷ Sign Up
Patent: 6650500
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 20916
Estimated Expiration: ⤷ Sign Up
Eurasian Patent Organization
Patent: 1791095
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 20916
Estimated Expiration: ⤷ Sign Up
Patent: 72742
Estimated Expiration: ⤷ Sign Up
Finland
Patent: 20916
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 62159
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 2182
Estimated Expiration: ⤷ Sign Up
Patent: 6080
Estimated Expiration: ⤷ Sign Up
Patent: 4252
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 29684
Estimated Expiration: ⤷ Sign Up
Patent: 85810
Estimated Expiration: ⤷ Sign Up
Patent: 17537899
Estimated Expiration: ⤷ Sign Up
Patent: 21073241
Estimated Expiration: ⤷ Sign Up
Patent: 23062189
Estimated Expiration: ⤷ Sign Up
Lithuania
Patent: 20916
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 17006089
Estimated Expiration: ⤷ Sign Up
Patent: 21006734
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 1696
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 20916
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 20916
Estimated Expiration: ⤷ Sign Up
Singapore
Patent: 201703806X
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 20916
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 2338802
Estimated Expiration: ⤷ Sign Up
Patent: 2644844
Estimated Expiration: ⤷ Sign Up
Patent: 170103768
Estimated Expiration: ⤷ Sign Up
Patent: 210156840
Estimated Expiration: ⤷ Sign Up
Patent: 240035908
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 47819
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering TAZVERIK around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Japan | 2017537899 | 癌を処置する方法 | ⤷ Sign Up |
Japan | 6255382 | ⤷ Sign Up | |
South Korea | 102061353 | ⤷ Sign Up | |
Turkey | 201904660 | ⤷ Sign Up | |
Russian Federation | 2677276 | СПОСОБЫ ЛЕЧЕНИЯ РАКА (METHODS OF TREATING CANCER) | ⤷ Sign Up |
Singapore | 11201502803V | SUBSTITUTED BENZENE COMPOUNDS | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |